Merck to initiate Phase II Keytruda trials on back of new data
This article was originally published in Scrip
Merck's anti-PD-1 drug Keytruda (pembrolizumab) shows promise in both gastric and bladder cancers, with overall response rates 31% and 24% respectively, according to new data released at ESMO this weekend.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.